Abstract:ASPP2 and iASPP bind to p53 through their conserved ANK-SH3 domains to respectively promote and inhibit p53-dependent cell apoptosis. While crystallography has indicated that these two proteins employ distinct surfaces of their ANK-SH3 domains to bind to p53, solution NMR data has suggested similar surfaces. In this study, we employed multi-scale molecular dynamics (MD) simulations combined with free energy calculations to reconcile the discrepancy in the binding modes. We demonstrated that the binding mode based solely on a single crystal structure does not enable iASPP's RT loop to engage with p53's C-terminal linker—a verified interaction. Instead, an ensemble of simulated iASPP-p53 complexes facilitates this interaction. We showed that the ensemble-average inter-protein contacting residues and NMR-detected interfacial residues qualitatively overlap on ASPP proteins, and the ensemble-average binding free energies better match experimental K D values compared to single crystallgarphy-determined binding mode. For iASPP, the sampled ensemble complexes can be grouped into two classes, resembling the binding modes determined by crystallography and solution NMR. We thus propose that crystal packing shifts the equilibrium of binding modes towards the crystallography-determined one. Lastly, we showed that the ensemble binding complexes are sensitive to p53's intrinsically disordered regions (IDRs), attesting to experimental observations that these IDRs contribute to biological functions. Our results provide a dynamic and ensemble perspective for scrutinizing these important cancer-related protein-protein interactions (PPIs). Solution NMR and crystallography often yield disparate results when determining the biologically relevant binding modes of protein-protein interactions. Through computational modeling, we successfully reconciled the discrepancies in binding modes reported by NMR and crystallography for the tumor suppressor protein p53 and its regulators, ASPP2, and iASPP. We demonstrated that the controversial binding modes determined by NMR and crystallography for iASPP-p53 are, in fact, the two major binding modes captured in free protein-protein binding simulations. Therefore, both reported binding modes are plausible, and crystal packing influences the preference for the mode captured in crystallography. Our results underscore the concept that proteins function through dynamic ensembles, and under physiological conditions, protein-protein interactions can have more than one binding mode. Using this ensemble binding framework, we explore the roles of disordered regions of p53 in complex formation, demonstrating how the overlooked IDRs can fine-tune protein-protein interactions.

Identification of a Novel Isoform of Iaspp and Its Interaction with P53

iASPP-SV, an Important iASPP isoform, participated in breast tumorigenesis/progression

Iaspp is Over-Expressed in Human Non-Small Cell Lung Cancer and Regulates the Proliferation of Lung Cancer Cells Through a P53 Associated Pathway

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors

Iasppsv Antagonizes Apoptosis Induced by Chemotherapeutic Agents in MCF-7 Cells and Mouse Thymocytes

Sertad1 Antagonizes Iaspp Function by Hindering Its Entrance into Nuclei to Interact with P53 in Leukemic Cells

Overexpression of Iaspp-Sv in Glioma is Associated with Poor Prognosis by Promoting Cell Viability and Antagonizing Apoptosis.

Oncogene Iaspp Enhances Self‐renewal of Hematopoietic Stem Cells and Facilitates Their Resistance to Chemotherapy and Irradiation

siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.

High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)

Iaspp Overexpression is Associated with Clinical Outcome in Spinal Chordoma and Influences Cellular Proliferation, Invasion, and Sensitivity to Cisplatin in Vitro.

iASPP protects the heart from ischemia injury by inhibiting p53 expression and cardiomyocyte apoptosis

The expression of iASPP in acute leukemias.

Effect of Iaspp on the Anti-Apoptosis and Genomic Instability of MCF-7

A Naturally Occurring 4-Bp Deletion in the Intron 4 of P53 Creates a Spectrum of Novel P53 Isoforms with Anti-Apoptosis Function

Protein Inhibitor of Activated Stat Y (piasy) and A Splice Variant Lacking Exon 6 Enhance Sumoylation but Are Not Essential for Embryogenesis and Adult Life

Reconciling ASPP-p53 binding mode discrepancies through an ensemble binding framework that bridges crystallography and NMR data

iASPP–PP1 complex is required for cytokinetic abscission by controlling CEP55 dephosphorylation

PIDD4, a Novel PIDD Isoform Without the LRR Domain, Can Independently Induce Cell Apoptosis in Cytoplasm

P53 Isoforms Can Regulate P53 Transcriptional Activity

SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing.